566 related articles for article (PubMed ID: 25026639)
1. A cautious view of putative precursors of serous carcinomas in the fallopian tubes of BRCA mutation carriers.
Cass I; Walts AE; Barbuto D; Lester J; Karlan B
Gynecol Oncol; 2014 Sep; 134(3):492-7. PubMed ID: 25026639
[TBL] [Abstract][Full Text] [Related]
2. p53 signature and serous tubal in-situ carcinoma in cases of primary tubal and peritoneal carcinomas and serous borderline tumors of the ovary.
Leonhardt K; Einenkel J; Sohr S; Engeland K; Horn LC
Int J Gynecol Pathol; 2011 Sep; 30(5):417-24. PubMed ID: 21804388
[TBL] [Abstract][Full Text] [Related]
3. Retrospective study of a 16 year cohort of BRCA1 and BRCA2 carriers presenting for RRSO: Prevalence of invasive and in-situ carcinoma, with follow-up.
Blok F; Dasgupta S; Dinjens WNM; Roes EM; van Beekhuizen HJ; Ewing-Graham PC
Gynecol Oncol; 2019 May; 153(2):326-334. PubMed ID: 30894273
[TBL] [Abstract][Full Text] [Related]
4. Tubal epithelial lesions in salpingo-oophorectomy specimens of BRCA-mutation carriers and controls.
Mingels MJ; Roelofsen T; van der Laak JA; de Hullu JA; van Ham MA; Massuger LF; Bulten J; Bol M
Gynecol Oncol; 2012 Oct; 127(1):88-93. PubMed ID: 22710074
[TBL] [Abstract][Full Text] [Related]
5. Proliferation in the normal FTE is a hallmark of the follicular phase, not BRCA mutation status.
George SH; Milea A; Shaw PA
Clin Cancer Res; 2012 Nov; 18(22):6199-207. PubMed ID: 22967960
[TBL] [Abstract][Full Text] [Related]
6. Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers.
Shaw PA; Rouzbahman M; Pizer ES; Pintilie M; Begley H
Mod Pathol; 2009 Sep; 22(9):1133-8. PubMed ID: 19543244
[TBL] [Abstract][Full Text] [Related]
7. A candidate precursor to serous carcinoma that originates in the distal fallopian tube.
Lee Y; Miron A; Drapkin R; Nucci MR; Medeiros F; Saleemuddin A; Garber J; Birch C; Mou H; Gordon RW; Cramer DW; McKeon FD; Crum CP
J Pathol; 2007 Jan; 211(1):26-35. PubMed ID: 17117391
[TBL] [Abstract][Full Text] [Related]
8. Support of the 'fallopian tube hypothesis' in a prospective series of risk-reducing salpingo-oophorectomy specimens.
Reitsma W; de Bock GH; Oosterwijk JC; Bart J; Hollema H; Mourits MJ
Eur J Cancer; 2013 Jan; 49(1):132-41. PubMed ID: 22921157
[TBL] [Abstract][Full Text] [Related]
9. Development of Peritoneal Carcinoma in women diagnosed with Serous Tubal Intraepithelial Carcinoma (STIC) following Risk-Reducing Salpingo-Oophorectomy (RRSO).
Stanciu PI; Ind TEJ; Barton DPJ; Butler JB; Vroobel KM; Attygalle AD; Nobbenhuis MAE
J Ovarian Res; 2019 May; 12(1):50. PubMed ID: 31128592
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes in patients with isolated serous tubal intraepithelial carcinoma (STIC): A comprehensive review.
Patrono MG; Iniesta MD; Malpica A; Lu KH; Fernandez RO; Salvo G; Ramirez PT
Gynecol Oncol; 2015 Dec; 139(3):568-72. PubMed ID: 26407480
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of risk-reducing salpingo-oophorectomy in BRCA1-2 variants and clinical outcomes of follow-up in patients with isolated serous tubal intraepithelial carcinoma (STIC).
Saccardi C; Zovato S; Spagnol G; Bonaldo G; Marchetti M; Alessandrini L; Tognazzo S; Guerriero A; Vitagliano A; Laganà AS; Noventa M
Gynecol Oncol; 2021 Nov; 163(2):364-370. PubMed ID: 34465478
[TBL] [Abstract][Full Text] [Related]
12. Pathological findings following risk-reducing salpingo-oophorectomy in BRCA mutation carriers: A systematic review and meta-analysis.
Cheng A; Li L; Wu M; Lang J
Eur J Surg Oncol; 2020 Jan; 46(1):139-147. PubMed ID: 31521389
[TBL] [Abstract][Full Text] [Related]
13. BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype?
Cass I; Holschneider C; Datta N; Barbuto D; Walts AE; Karlan BY
Obstet Gynecol; 2005 Dec; 106(6):1327-34. PubMed ID: 16319259
[TBL] [Abstract][Full Text] [Related]
14. Serous tubal intraepithelial carcinoma localizes to the tubal-peritoneal junction: a pivotal clue to the site of origin of extrauterine high-grade serous carcinoma (ovarian cancer).
Seidman JD
Int J Gynecol Pathol; 2015 Mar; 34(2):112-20. PubMed ID: 25675178
[TBL] [Abstract][Full Text] [Related]
15. The association of serous tubal intraepithelial carcinoma with gynecologic pathologies and its role in pelvic serous cancer.
Koç N; Ayas S; Uygur L
Gynecol Oncol; 2014 Sep; 134(3):486-91. PubMed ID: 25038287
[TBL] [Abstract][Full Text] [Related]
16. Outcome and Prognostic Impact of Surgical Staging in Serous Tubal Intraepithelial Carcinoma: A Cohort Study and Systematic Review.
Van der Hoeven NMA; Van Wijk K; Bonfrer SE; Beltman JJ; Louwe LA; De Kroon CD; Van Asperen CJ; Gaarenstroom KN
Clin Oncol (R Coll Radiol); 2018 Aug; 30(8):463-471. PubMed ID: 29691126
[TBL] [Abstract][Full Text] [Related]
17. Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status.
Manchanda R; Abdelraheim A; Johnson M; Rosenthal AN; Benjamin E; Brunell C; Burnell M; Side L; Gessler S; Saridogan E; Oram D; Jacobs I; Menon U
BJOG; 2011 Jun; 118(7):814-24. PubMed ID: 21392246
[TBL] [Abstract][Full Text] [Related]
18. Evidence for a dualistic model of high-grade serous carcinoma: BRCA mutation status, histology, and tubal intraepithelial carcinoma.
Howitt BE; Hanamornroongruang S; Lin DI; Conner JE; Schulte S; Horowitz N; Crum CP; Meserve EE
Am J Surg Pathol; 2015 Mar; 39(3):287-93. PubMed ID: 25581732
[TBL] [Abstract][Full Text] [Related]
19. Pathologic findings at risk-reducing salpingo-oophorectomy (RRSO) in germline BRCA mutation carriers with breast cancer: significance of bilateral RRSO at the optimal age in germline BRCA mutation carriers.
Lee YJ; Lee SW; Kim KR; Jung KH; Lee JW; Kim YM
J Gynecol Oncol; 2017 Jan; 28(1):e3. PubMed ID: 27670257
[TBL] [Abstract][Full Text] [Related]
20. [Morphologic changes of fallopian tubal epithelium in ovarian serous tumors].
Wen J; Shi JL; Shen DH; Chen YX; Song QJ
Zhonghua Bing Li Xue Za Zhi; 2012 Jul; 41(7):433-7. PubMed ID: 22932451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]